<DOC>
	<DOCNO>NCT00830440</DOCNO>
	<brief_summary>The purpose study evaluate safety initial efficacy EndoBarrier device compare diet control patient require weight loss prior Bariatric surgery . It randomize , prospective control , open label , pilot study 40 patient . Thiry patient receive implant EndoBarrier device 10 patient receive principle investigator 's standard care diet program . All patient treat 12 week exception last 10 device patient continue 24 week principle investigator determines safe best interest continue . The primary efficacy endpoint : - Assessment difference % excess weight loss 2 group Secondary endpoint : - Resolution Improvement type II Diabetic status define : - Resolution = patient diabetes medication normal diabetic blood parameter ( fast glucose ) - Improvement = normalize diabetic blood parameter ( fast glucose ) and/or reduction dose frequency diabetic medication - The percent patient achieve least 10 % excess weight loss calculate secondary outcome .</brief_summary>
	<brief_title>A Multicenter Study Pre-Surgical Weight Loss</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Age &gt; 18 year &lt; 55 year Male Female BMI &gt; 35 significant comorbidities ( i.e . hypertension , hyperlipidemia , diabetes ) &gt; 40 BMI &lt; 60 ( without comorbid condition ) History failure nonsurgical weight loss method Candidates RouxenY gastric bypass Patients willing comply study requirement Patients sign informed consent form Patients require prescription anticoagulation therapy Patients iron deficiency iron deficiency anemia Inflammatory bowel disease condition gastrointestinal tract , ulcer Crohn 's disease Treatment represent unreasonable risk patient Pancreatitis serious organic condition Symptomatic coronary artery disease pulmonary dysfunction Patients know gallstone prior implant Known infection time implant Severe coagulopathy , upper gastrointestinal bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasia Congenital acquire anomaly GI tract atresia stenoses Pregnant intention become pregnant next 12 month Unresolved alcohol drug addiction HIV Positive patient Patients hepatitis B C Mentally retard emotionally unstable , exhibit psychological characteristic , opinion investigator , make subject poor candidate device placement clinical trial Previous GI surgery could affect ability place sleeve function implant . Patients unable discontinue NSAIDs ( nonsteroidal antiinflammatory drug ) implant period H. pylorus positive patient ( Note : patient may enrol prior history successfully treat ) Patients receive weight loss medication Meridia Xenical Family patient history know diagnosis preexist symptom systemic lupus erythematosus , scleroderma autoimmune connective tissue disorder Patients gastroesophageal reflux disease ( GERD ) Patients history kidney stone Participating another ongoing investigational clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>